Citations to this article
Citation Information: J Clin Invest. 2020;130(12):6225-6227. https://doi.org/10.1172/JCI143292.
Abstract
Individuals with coronavirus disease 2019 (COVID-19) can develop pneumonia and a severe inflammatory response with excessive cytokine release known as the cytokine storm. The JAK inhibitor baricitinib, used to treat rheumatoid arthritis, reduces inflammation by modifying the cytokine pathway. In this issue of the JCI, Bronte, Ugel, and colleagues performed an observational longitudinal study to evaluate the use of baricitinib in 20 patients with COVID-19. The treated patients showed reduced levels of plasma IL-6, TNF, IL-1β, and phosphorylated STAT3 as well as swift lymphocyte restoration. Notably, these patients had a dramatically favorable clinical outcome. While bias can plague uncontrolled research, this study has biological credibility and warrants randomized, controlled studies.
Authors
David L. Thomas
Citations to this article (4)
| Title and authors | Publication | Year |
|---|---|---|
|
Study of kaempferol in the treatment of COVID-19 combined with Chikungunya co-infection by network pharmacology and molecular docking technology
Hossain MA, Sohel M, Sultana T, Hasan MI, Khan MS, Kibria KM, Mahmud SM, Rahman MH |
Informatics in medicine unlocked | 2023 |
|
Therapeutic potential of Coptis chinensis for arthritis with underlying mechanisms.
Li M, Tian F, Guo J, Li X, Ma L, Jiang M, Zhao J |
Frontiers in pharmacology | 2023 |
|
Clinical data mining reveals Gancao-Banxia as a potential herbal pair against moderate COVID‐19 by dual binding to IL-6/STAT3
Luo W, Ding R, Guo X, Zhan T, Tang T, Fan R, Wang Y |
Computers in Biology and Medicine | 2022 |
|
Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology.
Du HX, Zhu JQ, Chen J, Zhou HF, Yang JH, Wan HT |
Aging | 2021 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)